Since glutamine is well known as a treatment for sepsis (i.e., due to tissue protection, anti-inflammatory/immune reactions, preservation of tissue metabolic functions, and antioxidant activity/attenuation of inducible nitric oxide synthase expression) [36–39], we believed that early glutamine administration would also be beneficial to patients in the postresuscitation period. The gene discussed is NOS2; the disease is Sepsis.